Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells

American Journal of Veterinary Research

Volumn 67, Issue 6, 2006, Pages 1025-1032

  Bracklein, Thorsten ^a   Theise, Sandra ^a   Metzler, Alfred ^a   Spiess, Bernhard M ^a   Richter, Marianne ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MYXOVIRUS RESISTANCE PROTEIN; RECOMBINANT INTERFERON; RECOMBINANT OMEGA INTERFERON; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRBAGEN OMEGA;

ANIMAL CELL; ARTICLE; CAT; CELL TYPE; CONJUNCTIVA; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MALE; NONHUMAN; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; CATS; CONJUNCTIVA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; INTERFERON TYPE I; LEUKOCYTES; MALE;

FELIDAE; MURINAE;

EID: 33745636524     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.6.1025     Document Type: Article

References (59)

1. Staeheli P. Interferon-induced proteins and the antiviral state. Adv Virus Res 1990;38:147-200.
2. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-281.
3. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14:778-809, table of contents.
4. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus counter-measures. J Gen Virol 2000;81:2341-2364.
5. Pirovinc, M, Aguet M, Huber M, et al. Absence of detectable serum interferon in acute and chronic viral hepatitis. Hepatology 1986;6:645-647.
6. Cheng YS, Becker-Manley MF, Rucker RG, et al. Accumulation of guanylate binding proteins in patients treated with interferons. J Interferon Res 1988;8:385-391.
7. Schiller JH, Horisberger MA, Bittner G, et al. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle. J Biol Response Mod 1990;9:368-377.
8. Schattner A, Wallach D, Merlin G, et al. Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet 1981;2:497-500.
9. Goldstein D, Sielaff KM, Storer BE, et al. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferori-beta serine. J Natl Cancer Inst 1989;81:1061-1068.
10. Liberati AM, Horisberger MA, Garofani P, et al. Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia. J Interferon Res 1994;14:349-355.
11. Roers A, Hochkeppel HK, Horisberger MA, et al. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994; 169:807-813.
12. von Wussow P, Jakschies D, Hochkeppel HK, et al. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990;20:2015-2019.
13. Horisberger MA, De Staritzky K. Expression and stability of the Mx protein in different tissues of mice, in response to interferon inducers or to influenza virus infection. J Interferon Res 1989;9:583-590.
14. Lleonart R, Naf D, Browning H, et al. A novel, quantitative bioassay for type I interferon using a recombinant indicator cell line. Biotechnology (NY) 1990;8:1263-1267.
15. Towbin H, Schmitz A, Jakschies D, et al. A whole blood immunoassay for the interferon-inducible human Mx protein. J Interferon Res 1992;12:67-74.
16. Files JG, Gray JL, Do LT, et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998;18:1019-1024.
17. Witt PL, Goldstein D, Storer BE, et al. Absence of biological effects of orally administered interferon-beta ser. J interferon Res 1992;12:411-413.
18. Brod SA, Nelson L, Jin R, et al. Ingested interferon alpha induces Mx mRNA. Cytokine 1999; 11:492-499.
19. Gibson DM, Cotler S, Spiegel HE, et al. Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 1985;5:403-408.
20. Fleischmarn WR Jr, Koren S, Fleischmann CM, Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med 1992;201:200-207.
21. Horisberger MA. Interferon-induced human protein MxA is a GTPase which binds transiently to cellular proteins. J Virol 1992;66:4705-4709.
22. Ronni T, Melen K, Malygin A, et al. Control of IFN-iriducible MxA gene expression in human cells. J Immunol 1993;150:1715-1726.
23. Horisberger MA, Schrenk R, Staiger S, et al. Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid. Antiviral Res 1990;13:53-59.
24. Cocker FM, Howard PE, Harbour DA. Effect of human alpha-hybrid interferon on the course of feline viral rhinotracheltis. Vet Res 1987;120:391-393.
25. Cummins JM, Hutcheson DP, Cummins MJ, et al. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch Immunol Ther Exp 1993;41:193-197.
26. Cummins JM, Mock RE, Shive BW, et al. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet Immunol Immunopathol 1995;45:355-360.
27. Cummins JM, Tompkins MB, Olsen RG, et al. Oral use of human alpha interferon in cats. J Biol Response Mod 1988;7:513-523.
28. Lecce JG, Cummins JM, Richards AB. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Mol Biother 1990;2:211-216.
29. Weiss RC, Cummins JM, Richards AB. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J Am Vet Med Assoc 1991;199:1477-1481.
30. Zeidner NS, Myles MH, Mathiason-DuBard CK, et al. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 1990;34:1749-1756.
31. Bosio E, Beilharz MW, Watson MW, et al. Efficacy of lowdose oral use of type I interferon in cytomegalovirus infections in vivo. J Interferon Cytokine Res 1999;19:869-876.
32. Brod SA, Kerman RH, Nelson LD, et al. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Mult Scler 1997;3:1-7.
33. Meritet JF, Maury C, Tovey MG. Induction of tolerance to recombinant therapeutic proteins. J Interferon Cytokine Res 2001;21:1031-1038.
34. Nagler-Anderson C, Terhoust C, Bhan AK, et al. Mucosal antigen presentation and the control of tolerance and immunity. Trends Immunol 2001;22:120-122.
35. Brod SA, Khan M. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autommume encephalomyelitis. J Autoimmun 1996;9:11-20.
36. Smolin G. Biosynthetic human interferon treatment of herpetic keratitis. Trans Am Ophthalmol Soc 1983;81:785-824.
37. Sundmacher R, Neumann-Haefelin D, Cantell K. Successful treatment of dendritic keratitis with human leukocyte interferon. A controlled clinical study. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1976;201:39-45.
38. Neumann-Haefelin D, Sundmacher R, Sauter B, et al. Effect of human leukocyte interferon on vaccinia- and herpes virus-infected cell cultures and monkey corneas. Infect Immun 1975;12:148-155.
39. de Koning EW, van Bijsterveld OP, Cantell K. Combination therapy for dendritic keratitis with acyclovir and alpha-interferon. Arch Ophthalmol 1983;101:1866-1868.
40. Colin J, Chastel C, Renard G, et al. Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir. Am J Ophthalmol 1983;95:346-348.
41. Minkovitz JB, Pepose JS. Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. Cornea 1995;14:326-330.
42. Ueda Y, Sakurai T, Yanai A. Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization the product. J Vet Med Sci 1993;55:251-258.
43. Sakurai T, Ueda Y, Sato M, et al. Feline interferon product in silkworm by recombinant baculovirus. J Vet Med Sci 1992;54:563-565.
44. Truyen U, Blewaska S, Schultheiss U. Untersuchung der antiviralen Wirksamkeit von Interferon-Omega (IFN-ω) gegen ausgewählte Viren von Hund und Katze. Der praktische Tierarzt 2002;83:862-865.
45. Minagawa. T, Ishiwata K, Kajimoto T. Feline interferon-omega treatment on canine parvovirus infection. Vet Microbiol 1999;69:51-53.
46. Müller-Doblies D, Ackermann M, Metzler A. In vitro and in vivo detection of Mx gene products in bovine cells following stimulation with alpha/beta interferon and viruses. Clin Diagn Lab Immunol 2002;9:1192-1199.
47. Tovey MG, Maury C. Oromucosal interferon therapy: marked antiviral and antitumor activity. J Interferon Cytokine Res 1999;19:145-155.
48. Bocci V. Interleukins. Clinical pharmacokinetics and practical implications. Clin Pharmacokinet 1991;21:274-284.
49. Bocci V. Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Does an unorthodox route improve the therapeutic index of interferon? Clin Pharmacokinet 1991;21:411-417.
50. Taylor JL, Grossberg SE. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol 1998;25:23-29.
51. Pfeffer LM, Donner DB. The down-regulation of alpha-interferon receptors in human lymphoblastoid cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon. Cancer Res 1990;50:2654-2657.
52. Bocci V. Immunomodulators as local hormones: new insights regarding their clinical utilization. J Biol Response Mod 1985;4:340-352.
53. Taylor JL, O'Brien WJ. Interferon production and sensitivity of rabbit corneal epithelial and stromal cells. Invest Ophthalmol Vis Sci 1985;26:1502-1508.
54. Leib DA, Harrison TE, Laslo KM, et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999;189:663-672.
55. Abrams ME, Balish MJ, Brandt CR. IFN-alpha induces MxA gene expression in cultured human corneal fibroblasts. Exp Eye Res 1995;60:137-142.
56. Hilkens CM, Schlaak JF, Kerr IM. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J Immunol 2003;171:5255-5263.
57. Kaufman HE, Sugar J, Varnell ED. Effect of exogenous interferon on herpetic keratitis in rabbits and monkeys. Invest Ophthalmol 1973;12:378-380.
58. McGill JI, Collins P, Cantell K, et al. Optimal schedules for use of interferon in the corneas of rabbits with herpes simplex keratitis. J Infect Dis 1976;133:13-17.
59. de Koning EW, van Bijsterveld OP, Cantell K. Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine. Br J Ophthalmol 1982;66:509-512.